↓ Skip to main content

Dove Medical Press

Article Metrics

Development of oral immunomodulatory agents in the management of multiple sclerosis

Overview of attention for article published in Drug Design, Development and Therapy, May 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#50 of 1,849)
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

blogs
1 blog
twitter
1 tweeter
patent
17 patents

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
88 Mendeley
Title
Development of oral immunomodulatory agents in the management of multiple sclerosis
Published in
Drug Design, Development and Therapy, May 2011
DOI 10.2147/dddt.s10498
Pubmed ID
Authors

Richard Nicholas, Richard Nicholas, Giannetti, Ali Alsanousi, Muraro

Abstract

The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim of stopping future events. Thus the possible absence of any perceived benefits to the individual together with the long disease course, variable outcome, and a younger age group affected in MS makes side effects the major issue. The use of disease-modifying therapies as a whole needs to be placed in the context of a widening therapeutic indication where the use of these therapies is being justified at an increasingly early stage and in pre-MS syndromes such as clinically isolated and radiologically isolated syndromes where no fixed disability is likely to have accumulated. The five oral therapies discussed (cladribine, fingolimod, laquinimod, BG-12, and teriflunomide) have just completed Phase III studies and some have just been licensed. New oral drugs for MS need to be placed within this evolving marketplace where ease of delivery together with efficacy and side effects needs to be balanced against the known issues but also the known long-term safety of standard injectables.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
United States 1 1%
Uruguay 1 1%
Unknown 84 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 19%
Other 16 18%
Researcher 14 16%
Student > Bachelor 7 8%
Student > Doctoral Student 5 6%
Other 14 16%
Unknown 15 17%
Readers by discipline Count As %
Medicine and Dentistry 35 40%
Agricultural and Biological Sciences 9 10%
Neuroscience 8 9%
Nursing and Health Professions 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 11 13%
Unknown 17 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2021.
All research outputs
#1,236,282
of 19,296,398 outputs
Outputs from Drug Design, Development and Therapy
#50
of 1,849 outputs
Outputs of similar age
#7,807
of 138,775 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 10 outputs
Altmetric has tracked 19,296,398 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,849 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 138,775 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.